000143878 001__ 143878
000143878 005__ 20240229112611.0
000143878 0247_ $$2doi$$a10.1186/s12885-019-5600-x
000143878 0247_ $$2pmid$$apmid:31138244
000143878 0247_ $$2altmetric$$aaltmetric:61286973
000143878 037__ $$aDKFZ-2019-01440
000143878 041__ $$aeng
000143878 082__ $$a610
000143878 1001_ $$00000-0001-7803-0814$$aSalwender, Hans$$b0
000143878 245__ $$aRationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
000143878 260__ $$aHeidelberg$$bSpringer$$c2019
000143878 3367_ $$2DRIVER$$aarticle
000143878 3367_ $$2DataCite$$aOutput Types/Journal article
000143878 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1559891415_8884
000143878 3367_ $$2BibTeX$$aARTICLE
000143878 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143878 3367_ $$00$$2EndNote$$aJournal Article
000143878 520__ $$aDespite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of new drugs (i.e. bortezomib and lenalidomide) as induction and maintenance treatment in an intensified treatment concept, including high dose melphalan (200 mg/m2), has resulted in increased CR rates, and is considered the standard of care for younger patients. Elotuzumab in combination with lenalidomide and dexamethasone has given better results as lenalidomide and dexamethasone alone in a phase III trial. The GMMG-HD6 trial will be the first phase III trial investigating the role of elotuzumab in combination with bortezomib, lenalidomide and dexamethasone (VRD) induction/consolidation and lenalidomide maintenance within a high dose concept.GMMG-HD6 is a randomized, open, multicenter phase III trial. The planned recruitment number is 564 NDMM patients. All patients will receive 4 VRD cycles as induction and undergo peripheral blood stem cell mobilization and harvesting. Thereafter they will be treated with high dose melphalan therapy plus autologous stem cell transplantation followed by 2 cycles of VRD consolidation and lenalidomide maintenance. Patients in arm B1 + B2 will additionally receive elotuzumab in the induction phase, whereas patients in A2 + B2 will be treated with elotuzumab added to consolidation and maintenance. The primary endpoint of the trial is PFS. Secondary objectives and endpoints are OS, CR rates after induction therapy comparing the two arms VRD (A1 + A2) vs VRD + elotuzumab (B1 + B2), CR rates after consolidation treatment, best response to treatment during the study, time to progression (TTP), duration of response (DOR), toxicity and quality of life.Since this is the publication of a study protocol of an ongoing study, no results can be presented.This phase III trial is designed to evaluate whether the addition of elotuzumab to an intensified treatment concept with high dose melphalan chemotherapy plus autologous stem cell transplantation and induction, consolidation and maintenance treatment with bortezomib and lenalidomide is able to improve PFS compared to the same concept without elotuzumab.NCT02495922 on June 24th, 2015.
000143878 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143878 588__ $$aDataset connected to CrossRef, PubMed,
000143878 7001_ $$aBertsch, Uta$$b1
000143878 7001_ $$aWeisel, Katja$$b2
000143878 7001_ $$aDuerig, Jan$$b3
000143878 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b4$$udkfz
000143878 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b5$$udkfz
000143878 7001_ $$aBlau, Igor W$$b6
000143878 7001_ $$aRaab, Marc Steffen$$b7
000143878 7001_ $$aHillengass, Jens$$b8
000143878 7001_ $$aHose, Dirk$$b9
000143878 7001_ $$aHuhn, Stefanie$$b10
000143878 7001_ $$aHundemer, Michael$$b11
000143878 7001_ $$aAndrulis, Mindaugas$$b12
000143878 7001_ $$aJauch, Anna$$b13
000143878 7001_ $$aSeidel-Glaetzer, Andrea$$b14
000143878 7001_ $$aLindemann, Hans-Walter$$b15
000143878 7001_ $$aHensel, Manfred$$b16
000143878 7001_ $$aFronhoffs, Stefan$$b17
000143878 7001_ $$aMartens, Uwe$$b18
000143878 7001_ $$aHansen, Timon$$b19
000143878 7001_ $$aWattad, Mohammed$$b20
000143878 7001_ $$aGraeven, Ullrich$$b21
000143878 7001_ $$aMunder, Markus$$b22
000143878 7001_ $$aFenk, Roland$$b23
000143878 7001_ $$aHaenel, Mathias$$b24
000143878 7001_ $$aScheid, Christof$$b25
000143878 7001_ $$aGoldschmidt, Hartmut$$b26
000143878 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-019-5600-x$$gVol. 19, no. 1, p. 504$$n1$$p504$$tBMC cancer$$v19$$x1471-2407$$y2019
000143878 909CO $$ooai:inrepo02.dkfz.de:143878$$pVDB
000143878 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143878 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143878 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143878 9141_ $$y2019
000143878 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000143878 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143878 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143878 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143878 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143878 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000143878 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000143878 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000143878 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000143878 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143878 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143878 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143878 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143878 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143878 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143878 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000143878 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000143878 980__ $$ajournal
000143878 980__ $$aVDB
000143878 980__ $$aI:(DE-He78)C060-20160331
000143878 980__ $$aUNRESTRICTED